Partial agonists of dopamine receptors: clinical effects and dopamine receptor interactions in combining aripiprazole with a full antagonist in treating psychosis

被引:1
|
作者
Cookson, John [1 ,2 ]
Pimm, Jonathan [2 ]
Reynolds, Gavin [3 ,4 ]
机构
[1] Royal London Hosp, London, England
[2] Mile End Hosp, Tower Hamlets Ctr Mental Hlth, East London NHS Fdn Trust, London, England
[3] Queens Univ, Belfast, North Ireland
[4] Sheffield Hallam Univ, Biomol Sci Res Ctr, Sheffield, England
关键词
Antipsychotics; drug interactions and side-effects; neuroendocrinology; polypharmacy; schizophrenia; METABOLIC DISTURBANCES; DOUBLE-BLIND; SCHIZOPHRENIA; RISPERIDONE; ANTIPSYCHOTICS; OLANZAPINE; CLOZAPINE; BINDING; WEIGHT;
D O I
10.1192/bja.2022.86
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Partial agonists of dopamine receptors are used in combination with full antagonists in treating psychosis, either to mitigate side-effects or in the hope of increasing effectiveness. We examine how combinations may affect the occupancy of D-2/D-3 dopamine receptors and explore how these can explain the outcomes in the light of the dopamine hypothesis of psychosis. The combinations considered here are from published studies combining aripiprazole with amisulpride, with risperidone in people with hyperprolactinaemia and with olanzapine to mitigate weight gain. We discuss possible worsening of symptoms by the addition of a partial agonist or switching. We also examine the potentially adverse interaction with a full antagonist such as haloperidol given during a subsequent relapse to control severe agitation.
引用
收藏
页码:158 / 165
页数:8
相关论文
共 50 条
  • [1] Partial agonists of dopamine receptors: receptor theory and the dopamine hypothesis of psychosis
    Cookson, John
    Pimm, Jonathan
    BJPSYCH ADVANCES, 2023, 29 (02) : 141 - 144
  • [2] Partial agonists of dopamine receptors: mechanisms and clinical effects of aripiprazole, brexpiprazole and cariprazine
    Cookson, John
    Pimm, Jonathan
    BJPSYCH ADVANCES, 2023, 29 (02) : 145 - 150
  • [3] On the effects of partial agonists of dopamine receptors for the treatment of schizophrenia
    Koch, M.
    PHARMACOPSYCHIATRY, 2007, 40 : S34 - S39
  • [4] The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?
    Lippi, Matteo
    Fanelli, Giuseppe
    Fabbri, Chiara
    De Ronchi, Diana
    Serretti, Alessandro
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2022, 37 (06) : 263 - 275
  • [5] Partial agonists of dopamine receptors: theoretical principles of combining antipsychotics including partial agonists to treat schizophrenia
    Cookson, John
    Pimm, Jonathan
    Brentnall, Andrew
    BJPSYCH ADVANCES, 2023, 29 (02) : 151 - 157
  • [6] Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?
    Mohr, Pavel
    Masopust, Jiri
    Kopecek, Miloslav
    FRONTIERS IN PSYCHIATRY, 2022, 12
  • [7] TRANSDIHYDROLISURIDE, A PARTIAL DOPAMINE RECEPTOR ANTAGONIST - EFFECTS ON MONOAMINE METABOLISM
    KEHR, W
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1984, 97 (1-2) : 111 - 119
  • [8] REPEATED STIMULATION OF DOPAMINE-D1 RECEPTORS ENHANCES THE EFFECTS OF DOPAMINE RECEPTOR AGONISTS
    WHITE, FJ
    HU, XT
    BROODERSON, RJ
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 191 (03) : 497 - 499
  • [9] Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties
    Wood, Martyn D.
    Scott, Claire
    Clarke, Kirsten
    Westaway, Julie
    Davies, Ceri H.
    Reavill, Charlie
    Hill, Mark
    Rourke, Claire
    Newson, Michael
    Jones, Declan N. C.
    Forbes, Ian T.
    Gribble, Andrew
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 546 (1-3) : 88 - 94
  • [10] In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors
    Tadori, Yoshihiro
    Forbes, Robert A.
    McQuade, Robert D.
    Kikuchi, Tetsuro
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2011, 668 (03) : 355 - 365